Author & reference | Year | Country | Cancer type | Patient size | Sample type | Method | Expression level | HR | Survival point | P value | Follow-up time | extraction | Quartiles of GDF-15 | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Li et al. [8] | 2016 | China | CRC | 138 | Serum | ELISA | Increased | 1.915 | OS | 0.045 | Unclear | Directly | / | 6 |
Wang et al. [13] | 2017 | China | CRC | 94 | Serum | ELISA | Increased | 2.917 | TSS | 0.0005 | Average: 43 months | Directly | / | 8 |
2.607 | TSS | 0.007 | ||||||||||||
Wallin et al. [9] | 2011 | Sweden | CRC | 320 | Plasma | SP-PLA | Increased | 2.11 | OS | 0.002 | Median: 6 years | Directly | / | 8 |
Brown et al. [10] | 2003 | Australia | CRC | 261 | Serum | ELISA | Increased | 2.2 | OS | 0.0034 | 60 months | Directly | / | 8 |
Mehta et al. [11] | 2015 | America | CRC | 618 | Plasma | ELISA | Increased | 1.88 | OS | < 0.0001 | Median: 9.2 years | Directly | Quartile2 | 8 |
Increased | 1.77 | OS | 0.0002 | |||||||||||
Increased | 1.74 | OS | 0.0002 | |||||||||||
Increased | 1.94 | CSS | 0.003 | |||||||||||
Increased | 1.65 | CSS | 0.01 | |||||||||||
Increased | 1.67 | CSS | 0.009 | |||||||||||
Increased | 2.51 | OS | < 0.0001 | Quartile3 | ||||||||||
Increased | 2.55 | OS | 0.0002 | |||||||||||
Increased | 2.54 | OS | 0.0002 | |||||||||||
Increased | 2.64 | CSS | 0.003 | |||||||||||
Increased | 2.6 | CSS | 0.01 | |||||||||||
Increased | 2.67 | CSS | 0.009 | |||||||||||
Increased | 2.85 | OS | < 0.0001 | Quartile4 | ||||||||||
Increased | 2.63 | OS | 0.0002 | |||||||||||
Increased | 2.63 | OS | 0.0002 | |||||||||||
Increased | 2.73 | CSS | 0.003 | |||||||||||
Increased | 2.34 | CSS | 0.01 | |||||||||||
Increased | 2.4 | CSS | 0.009 | |||||||||||
Fisher et al. [22] | 2015 | Australia | EC | 138 | Plasma | ELISA | Increased | 2.91 | OS | 0.076 | 60 months | Directly | / | 9 |
3.87 | OS | 0.048 | ||||||||||||
Wang et al. [21] | 2014 | China | ESCC | 286 | Serum | ELISA | Increased | 2.557 | TSS | 0.002 | Average: 30 months | Directly | / | 8 |
2.625 | TSS | 0.005 | ||||||||||||
1.739 | RFS | 0.047 | ||||||||||||
1.789 | RFS | 0.050 | ||||||||||||
Skipworth et al. [14] | 2010 | Australia | OGC | 293 | Plasma | ELISA | Increased | 1.549 | OS | 0.036 | Over 1500 days | Directly | / | 8 |
Blanco-Calvo et al. [15] | 2014 | Spain | GC | 52 | Serum | ELISA | Increased | 3.843 | OS | 0.001 | Median:118.9 weeks | Directly | / | 8 |
3.608 | PFS | < 0.001 |